
Neurocrine Biosciences NBIX
$ 127.8
0.09%
Annual report 2025
added 02-11-2026
Neurocrine Biosciences P/E Ratio 2011-2026 | NBIX
Annual P/E Ratio Neurocrine Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 34.9 | 51.7 | 64.4 | 83.4 | 25.1 | 251 | 373 | -53.8 | -24.7 | -40.4 | -41.5 | -24.9 | 115 | 13.6 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 373 | -53.8 | 59.1 |
P/E Ratio of other stocks in the Biotechnology industry
| Issuer | P/E Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-0.612 | - | 2.43 % | $ 254 M | ||
|
Amgen
AMGN
|
25.7 | $ 350.62 | 0.81 % | $ 189 B | ||
|
Heron Therapeutics
HRTX
|
-9.82 | $ 0.8 | 2.35 % | $ 133 M | ||
|
Altimmune
ALT
|
-3.61 | $ 3.46 | 3.44 % | $ 305 M | ||
|
I-Mab
IMAB
|
-0.236 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
55.7 | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
2.49 K | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M | ||
|
Ascendis Pharma A/S
ASND
|
-19.2 | $ 219.42 | -1.11 % | $ 5 B | ||
|
Midatech Pharma plc
MTP
|
-14.5 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.57 | - | -1.52 % | $ 24.7 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-1.71 | - | - | $ 26.5 M | ||
|
ARCA biopharma
ABIO
|
-5.78 | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
-4.94 | - | 5.93 % | $ 314 M | ||
|
Incyte Corporation
INCY
|
15.1 | $ 90.74 | -0.04 % | $ 17.7 B | ||
|
AgeX Therapeutics
AGE
|
-0.00095 | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
-0.0662 | - | -24.86 % | $ 820 K | ||
|
Albireo Pharma
ALBO
|
-15.8 | - | -0.23 % | $ 916 M | ||
|
Inovio Pharmaceuticals
INO
|
-1.63 | $ 1.62 | 2.22 % | $ 35.9 M | ||
|
Aileron Therapeutics
ALRN
|
-0.608 | - | 10.36 % | $ 9.8 M | ||
|
Acasti Pharma
ACST
|
-4.26 | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
38.8 | - | - | - | ||
|
Avenue Therapeutics
ATXI
|
-0.0465 | - | -52.27 % | $ 4.45 M | ||
|
Adverum Biotechnologies
ADVM
|
-0.583 | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
-0.463 | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
-0.0388 | - | -9.65 % | $ 45.9 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-0.203 | - | - | $ 7.46 M | ||
|
Cullinan Management
CGEM
|
-4.09 | $ 12.92 | 1.41 % | $ 778 M | ||
|
Inventiva S.A.
IVA
|
-10.8 | $ 6.13 | 6.06 % | $ 138 M | ||
|
Atreca
BCEL
|
-0.504 | - | -11.76 % | $ 5.79 M | ||
|
BioDelivery Sciences International
BDSI
|
3.63 | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
-392 | - | 0.49 % | $ 251 B | ||
|
KalVista Pharmaceuticals
KALV
|
-4.2 | $ 16.76 | -1.41 % | $ 832 M | ||
|
Calithera Biosciences
CALA
|
-8.34 | - | -10.95 % | $ 876 K | ||
|
Cara Therapeutics
CARA
|
-0.457 | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
-0.0138 | - | - | $ 3.74 B | ||
|
Bellerophon Therapeutics
BLPH
|
-3.96 | - | -74.18 % | $ 955 K | ||
|
Kamada Ltd.
KMDA
|
-121 | $ 8.23 | -0.24 % | $ 260 M | ||
|
Checkpoint Therapeutics
CKPT
|
-2.85 | - | - | $ 169 M | ||
|
Karyopharm Therapeutics
KPTI
|
-0.000957 | $ 7.06 | -7.47 % | $ 860 K | ||
|
Clovis Oncology
CLVS
|
-0.873 | - | -7.23 % | $ 13 M | ||
|
Keros Therapeutics
KROS
|
5.9 | $ 11.27 | 2.83 % | $ 419 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-3.48 | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
-8.58 | - | - | $ 867 M | ||
|
Denali Therapeutics
DNLI
|
-7.19 | $ 21.23 | 5.26 % | $ 3.49 B | ||
|
Longeveron
LGVN
|
-743 | $ 0.95 | -3.52 % | $ 16.7 B | ||
|
Akero Therapeutics
AKRO
|
-12.9 | - | - | $ 3.67 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
-6.11 | $ 4.3 | 1.3 % | $ 714 M | ||
|
Akouos
AKUS
|
-1.98 | - | 0.23 % | $ 488 M | ||
|
AIkido Pharma
AIKI
|
-1.33 | - | 1.93 % | $ 17.4 M |